Heart Failure with Preserved Ejection Fraction: Hypertension, Diabetes, Obesity/Sleep Apnea, and Hypertrophic and Infiltrative Cardiomyopathy

Heart Failure Clinics

Volumn 4, Issue 1, 2008, Pages 87-97

  Desai, Akshay ^a   Fang, James C ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BUSULFAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOT DERIVATIVE; LOSARTAN; RAMIPRIL; SEROTONIN AGONIST; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AMYLOIDOSIS; BLOOD PRESSURE REGULATION; CARCINOID SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG TOXICITY; ENDOTHELIAL DYSFUNCTION; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEMOCHROMATOSIS; HIGH RISK PATIENT; HUMAN; HURLER SYNDROME; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IDIOPATHIC CARDIOMYOPATHY; INFILTRATIVE CARDIOMYOPATHY; INSULIN RESISTANCE; LOEFFLER PNEUMONIA; OBESITY; PATHOPHYSIOLOGY; PRESERVED EJECTION FRACTION; PREVALENCE; PSEUDOXANTHOMA ELASTICUM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RISK ASSESSMENT; SARCOIDOSIS; SCLERODERMA; SLEEP APNEA SYNDROME; TREATMENT INDICATION;

AMYLOIDOSIS; CARDIOMYOPATHY, HYPERTROPHIC; DIABETES MELLITUS; HEART FAILURE; HUMANS; HYPERTENSION; OBESITY; SLEEP APNEA SYNDROMES;

EID: 39749098677     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.11.001     Document Type: Review

References (105)

1. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161 7 (2001) 996-1002
2. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 275 20 (1996) 1557-1562
3. Levy D., Anderson K.M., Savage D.D., et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108 1 (1988) 7-13
4. Haider A.W., Larson M.G., Franklin S.S., et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138 1 (2003) 10-16
5. Chae C.U., Pfeffer M.A., Glynn R.J., et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 281 7 (1999) 634-639
6. Verdecchia P., Carini G., Circo A., et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38 7 (2001) 1829-1835
7. Devereux R.B. Is the electrocardiogram still useful for detection of left ventricular hypertrophy?. Circulation 81 3 (1990) 1144-1146
8. Eberli F.R., Apstein C.S., Ngoy S., et al. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 70 5 (1992) 931-943
9. Aurigemma G.P., Silver K.H., Priest M.A., et al. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 26 1 (1995) 195-202
10. Rosen B.D., Edvardsen T., Lai S., et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis. Circulation 112 7 (2005) 984-991
11. Mitchell G.F., Guo C.Y., Benjamin E.J., et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation 115 20 (2007) 2628-2636
12. Zieman S.J., Melenovsky V., and Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25 5 (2005) 932-943
13. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115 15 (2007) 1982-1990
14. Shapiro B.P., Lam C.S., Patel J.B., et al. Acute and chronic ventricular-arterial coupling in systole and diastole. Insights from an elderly hypertensive model. Hypertension 50 3 (2007) 503-511
15. Mitchell G.F., Tardif J.C., Arnold J.M., et al. Pulsatile hemodynamics in congestive heart failure. Hypertension 38 6 (2001) 1433-1439
16. Tsioufis C., Chatzis D., Dimitriadis K., et al. Left ventricular diastolic dysfunction is accompanied by increased aortic stiffness in the early stages of essential hypertension: a TDI approach. J Hypertens 23 9 (2005) 1745-1750
17. Patrianakos A.P., Parthenakis F.I., Karakitsos D., et al. Relation of proximal aorta stiffness to left ventricular diastolic function in patients with end-stage renal disease. J Am Soc Echocardiogr 20 3 (2007) 314-323
18. Mitchell G.F., Vasan R.S., Keyes M.J., et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 297 7 (2007) 709-715
19. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 9 (2006) 1213-1225
20. Melenovsky V., Borlaug B.A., Rosen B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 49 2 (2007) 198-207
21. Zile M.R., Baicu C.F., and Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 19 (2004) 1953-1959
22. Hundley W.G., Kitzman D.W., Morgan T.M., et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38 3 (2001) 796-802
23. Kitzman D.W., Higginbotham M.B., Cobb F.R., et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 17 5 (1991) 1065-1072
24. Chen C.H., Nakayama M., Talbot M., et al. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol 33 6 (1999) 1602-1609
25. Borlaug B.A., Melenovsky V., Russell S.D., et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114 20 (2006) 2138-2147
26. Solomon S.D., Janardhanan R., Verma A., et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369 (2007) 2079-2087
27. Wachtell K., Bella J.N., Rokkedal J., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105 9 (2002) 1071-1076
28. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278 3 (1997) 212-216
29. Gueyffier F., Bulpitt C., Boissel J.P., et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 353 9155 (1999) 793-796
30. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275 19 (1996) 1507-1513
31. Koren M.J., Ulin R.J., Koren A.T., et al. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15 12 (2002) 1021-1028
32. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 21 (2002) 2512-2517
33. Rocha R., and Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 970 (2002) 89-100
34. Rocha R., Martin-Berger C.L., Yang P., et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 12 (2002) 4828-4836
35. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 23 (2001) 1689-1697
36. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
37. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102 22 (2000) 2700-2706
38. Davis B.R., Piller L.B., Cutler J.A., et al. Role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 113 18 (2006) 2201-2210
39. Warner Jr. J.G., Metzger D.C., Kitzman D.W., et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 33 6 (1999) 1567-1572
40. Thurmann P.A., Kenedi P., Schmidt A., et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 98 19 (1998) 2037-2042
41. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 1 (2003) 41-46
42. Mitchell G.F., Arnold J.M., Dunlap M.E., et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. Eur J Heart Fail 8 2 (2006) 191-197
43. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
44. Nesto R.W. Pharmacological treatment and prevention of heart failure in the diabetic patient. Rev Cardiovasc Med 5 1 (2004) 1-8
45. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 1 (1974) 29-34
46. Parker A.B., Yusuf S., and Naylor C.D. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. Am Heart J 144 6 (2002) 941-947
47. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 6 (2000) 1628-1637
48. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
49. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47 1 (2006) 76-84
50. Aguilar D., Solomon S.D., Kober L., et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110 12 (2004) 1572-1578
51. Shindler D.M., Kostis J.B., Yusuf S., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77 11 (1996) 1017-1020
52. Waller B.F., Palumbo P.J., Lie J.T., et al. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 69 4 (1980) 498-506
53. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102 9 (2000) 1014-1019
54. Devereux R.B., Roman M.J., Paranicas M., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101 19 (2000) 2271-2276
55. Di Bello V., Talarico L., Picano E., et al. Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. J Am Coll Cardiol 25 6 (1995) 1408-1415
56. Hardin N.J. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis 7 2 (1996) 99-108
57. Perez J.E., McGill J.B., Santiago J.V., et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 19 6 (1992) 1154-1162
58. Fang Z.Y., Prins J.B., and Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25 4 (2004) 543-567
59. Fang Z.Y., Yuda S., Anderson V., et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 41 4 (2003) 611-617
60. Hayat S.A., Patel B., Khattar R.S., et al. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 107 6 (2004) 539-557
61. Rodrigues B., Cam M.C., and McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180 1-2 (1998) 53-57
62. Golfman L., Dixon I.M., Takeda N., et al. Differential changes in cardiac myofibrillar and sarcoplasmic reticular gene expression in alloxan-induced diabetes. Mol Cell Biochem 200 1-2 (1999) 15-25
63. Sowers J.R., Epstein M., and Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37 4 (2001) 1053-1059
64. Zieman S., and Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail 10 3 (2004) 144-149 [quiz: 150-1]
65. Cockcroft J.R., Webb D.J., and Wilkinson I.B. Arterial stiffness, hypertension and diabetes mellitus. J Hum Hypertens 14 6 (2000) 377-380
66. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 19 (2002) 2570-2581
67. Zola B., Kahn J.K., Juni J.E., et al. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab 63 1 (1986) 208-214
68. Gress T.W., Nieto F.J., Shahar E., et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342 13 (2000) 905-912
69. van Hoeven K.H., and Factor S.M. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82 3 (1990) 848-855
70. Liu J.E., Palmieri V., Roman M.J., et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 37 7 (2001) 1943-1949
71. Taegtmeyer H., McNulty P., and Young M.E. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105 14 (2002) 1727-1733
72. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipiril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. [published erratum appears in Lancet 2000;356:860]. Lancet 355 (2000) 253-259
73. The PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
74. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy. N Engl J Med 345 12 (2001) 861-869
75. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 1004-1010
76. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 19 (2006) 2338-2345
77. McMurray J. Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger. Eur Heart J 27 19 (2006) 2257-2259
78. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 9386 (2003) 777-781
79. Carson P., Massie B.M., McKelvie R., et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 11 8 (2005) 576-585
80. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 5 (2002) 305-313
81. Horwich T.B., Fonarow G.C., Hamilton M.A., et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 3 (2001) 789-795
82. Kenchaiah S., Pocock S.J., Wang D., et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 116 6 (2007) 627-636
83. Taylor J.A., Christenson R.H., Rao K., et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 152 6 (2006) 1071-1076
84. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328 17 (1993) 1230-1235
85. Bradley T.D., and Floras J.S. Sleep apnea and heart failure: Part I: obstructive sleep apnea. Circulation 107 12 (2003) 1671-1678
86. Fung J.W., Li T.S., Choy D.K., et al. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 121 2 (2002) 422-429
87. Kaneko Y., Floras J.S., Usui K., et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348 13 (2003) 1233-1241
88. Sin D.D., Logan A.G., Fitzgerald F.S., et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 102 1 (2000) 61-66
89. Bradley T.D., Logan A.G., Kimoff R.J., et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 19 (2005) 2025-2033
90. Kushwaha S.S., Fallon J.T., and Fuster V. Restrictive cardiomyopathy. N Engl J Med 336 4 (1997) 267-276
91. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 15 (2000) 1077-1084
92. Bertog S.C., Thambidorai S.K., Parakh K., et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 43 8 (2004) 1445-1452
93. Joshi R., Abraham S., and Kumar A.S. New approach for complete endocardiectomy in left ventricular endomyocardial fibrosis. J Thorac Cardiovasc Surg 125 1 (2003) 40-42
94. Ho C.Y., and Seidman C.E. A contemporary approach to hypertrophic cardiomyopathy. Circulation 113 24 (2006) e858-e862
95. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 287 10 (2002) 1308-1320
96. Semsarian C., Ahmad I., Giewat M., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 109 8 (2002) 1013-1020
97. Ho C.Y., Sweitzer N.K., McDonough B., et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105 25 (2002) 2992-2997
98. Elliott P., and McKenna W.J. Hypertrophic cardiomyopathy. Lancet 363 9424 (2004) 1881-1891
99. Falk R.H., Comenzo R.L., and Skinner M. The systemic amyloidoses. N Engl J Med 337 13 (1997) 898-909
100. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 112 13 (2005) 2047-2060
101. Dubrey S.W., Cha K., Anderson J., et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91 2 (1998) 141-157
102. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 2 (2005) 186-193
103. Seldin D.C., Anderson J.J., Sanchorawala V., et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 104 6 (2004) 1888-1893
104. Dubrey S.W., Burke M.M., Hawkins P.N., et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 23 10 (2004) 1142-1153
105. Suhr O.B., Herlenius G., Friman S., et al. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 6 3 (2000) 263-276